# A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)

> **NCT01213316** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 451 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT01213316
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213316, "A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01213316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*